CA-PTW
11.2.2021 15:02:05 CET | Business Wire | Press release
PTW continues on their mission to be the go-to partner for innovation in the games industry with the business acquisition of premier art studio 5518 Studios. The industry-leading video games and tech services outsourcer announced their business acquisition of Los Angeles-based 5518 Studios; PTW is a long-time industry leader with an established and diverse dossier of top-tier clients and nearly 3 decades of experience in the games industry. PTW’s work spans across all platforms and all genres.
5518’s expertise ranges from high-quality concept & illustration art to character modeling & animation, along with everything in-between; PTW’s expansion ensures a greater range of skills, depth of talent, and overall expertise for their partners across the globe. Today’s announcement is an exciting step forward in PTW’s mission to provide full end-to-end co-development services to partners in the growing global games industry.
“Our mission is to revolutionize the digital entertainment sphere; adding 5518 to our team enables us to be one of the top development studios in the world. We will merge our existing game development brand- Orange Rock Studios- with 5518 under one name; our new brand will be perfectly poised to work alongside top-notch developers and publishers, building the best games & digital experiences around the world,” said Kasturi Rangan, Chief Product Officer of PTW. “When it comes to game development, we will now be a one-stop shop for external partnerships,” Rangan concluded.
PTW will be merging both Orange Rock and 5518 under a new name- 1518 Studios. The new brand will have a much stronger offering encompassing art, end-end game development, live ops, porting, product development, and staff augmentation (across Mobile, PC & Console). Michael Casalino, CEO and Co-founder of 5518 Studios added, “Our values and mission align so well with those of PTW; we each believe in strong relationships built on trust, passion, good communication, and high-quality games services.” 5518 COO and CO-founder Maxim Miheyenko concluded, “We are so excited to join the PTW family of brands.”
PTW CEO Deborah Kirkham concluded, “We are happy to welcome 5518 Studios and our new teams in Los Angeles, St. Petersburg, and Moscow to the PTW family. Expanding our global presence in the games industry is an important step in our mission of providing the best talent and the best technology to our partners around the world. Michael, Maxim, and their teams provide a level of expertise and energy which we can’t wait to bring to our partners.”
About PTW
PTW is a leading games, digital entertainment and interactive media solutions provider with 35 offices in 11 countries worldwide. Our range of services include quality assurance, localization, customer experience, engineering and development services, and audio production services. PTW brings nearly 3 decades of experience and the infrastructure to create customized support for projects and clients of all sizes.
PTW, comprised of global subsidiaries, is a UK-based holding company formed in 2016 under the umbrella of Poletowin Pitcrew Holdings, Inc. which is listed on the 1st Section of Tokyo Stock Exchange as 3657. POLE TO WIN is a registered trademark of Pole To Win Co., Ltd. in Japan and other countries. All rights reserved. For more information, visit https://www.ptw.com/
The PTW group includes SIDE , 1518 Studios , Entalize , The Game Dev Show , and OR Esports .
Stay connected with PTW on Facebook , Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005010/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom